CDK4 and breast carcinoma: To test the potential of RMC-6272 in CDK4/6 inhibitor resistant breast cancers, we developed palbociclib-resistant (PalboR) MCF-7, ZR-75-1, and T47D breast cancer cell lines through chronic treatment (Fig. 6A, Supplementary Fig. 4A, B).